Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Triple Negative Breast Cancer (TNBC), Early Setting”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Not applicableNot Yet RecruitingNCT07551765
What this trial is testing

Diet-drive Gut Microbiome and Outcome in Patients With Early-stage Triple-negative Breast Cancer Undergoing Neoadjuvant Chemotherapy and Immunotherapy.

Who this might be right for
Triple Negative Breast Cancer (TNBC), Early Setting
Barts & The London NHS Trust 300
Testing effectiveness (Phase 2)Ended earlyNCT06067061
What this trial is testing

"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer

Who this might be right for
Triple Negative Breast Neoplasms
Institut Curie 2
Testing effectiveness (Phase 2)Looking for participantsNCT06831955
What this trial is testing

LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer (TNBC), Early Setting
Universitaire Ziekenhuizen KU Leuven 356
Large-scale testing (Phase 3)Not Yet RecruitingNCT07486687
What this trial is testing

Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy

Who this might be right for
Triple Negative Breast Cancer (TNBC), Early SettingEarly Stage Triple-Negative Breast CarcinomaTriple -Negative Breast Cancer+2 more
The Netherlands Cancer Institute 1,000